Skip to main content

Collins Helen Louise's Form 4 filing

Enliven Therapeutics, Inc. (ELVN) · filed Mar 11, 2026

Accession no.
0001701247-26-000003
Filed
Mar 11, 2026
Trade date
Mar 9-10, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.20M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Collins Helen LouiseCIK 0001701247Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 9, 2026Common StockMOption exerciseAcquired+29,871$2.48+$74,080.0854,871Direct
Mar 9, 2026Common StockSSaleDisposed−29,871$30.02−$896,727.4225,000Direct
Mar 10, 2026Common StockMOption exerciseAcquired+10,129$2.48+$25,119.9235,129Direct
Mar 10, 2026Common StockSSaleDisposed−10,129$30.19−$305,794.5125,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 9, 2026Common StockMOption exerciseDisposed−29,871$0.00$0191,397Direct
Mar 10, 2026Common StockMOption exerciseDisposed−10,129$0.00$0181,268Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)